[Comparison of intracellular actin of thymosin alpha-1 and thymic serum factor].

P. Deschaux,A. Doublet,R. Fontanges

1982-01-25

Abstract:

What problem does this paper attempt to address?

Neutrophil-lymphocyte Ratio As a Prognostic Factor for Stereotactic Body Radiotherapy Treatment of Metastatic Liver Tumors.

Xuyun Xie,Jingjing Shan,Xuan Zhou,Hai Liu,Xiaonan Sun

DOI: https://doi.org/10.21037/tcr-20-1335a

2020-01-01

Translational Cancer Research

Abstract:BACKGROUND:The neutrophil-lymphocyte ratio (NLR) has been proposed as an indicator of systemic inflammatory response and may be able to predict clinical outcomes in patients with malignant solid tumors. However, the relationship between NLR and the prognosis of liver metastasis after stereotactic body radiotherapy (SBRT) is not well established.METHODS:Patients with liver metastatic tumors who underwent SBRT in our center between 2015 and 2018 were enrolled, and their data were retrospectively analyzed. The patient' baseline total white blood cell (WBC), neutrophil, lymphocyte, and platelet counts were recorded, along with their mean platelet volume (MPV) and red blood cell distribution width (RDW). The cut-off values for NLR and platelet-lymphocyte ratio (PLR) were determined by receiver operating characteristic (ROC) curves. Local control (LC) and overall survival (OS) were calculated using the Kaplan-Meier method. The Cox proportional hazards model was used to study significant variable line and factors associated with OS.RESULTS:A total of 65 patients with 82 lesions were enrolled. The median duration follow-up was 21 months. The local control (LC) rate was 76.8%, and the 1- and 2-year OS rates were 70.7% and 46.1%, respectively. The cut-off values of NLR and PLR were 3.16 and 201.33, respectively. Multivariate analysis identified the NLR cut-off value as a potential independent indicator of inferior OS [P=0.005, HR =3.317 (95% CI, 1.433-7.678)]. Biological effective dose (BED) was also associated with OS (P=0.035, HR =0.984 (95% CI, 0.969-0.999)].CONCLUSIONS:NLR showed a strong association with LC and OS, which could serve as a predictive guide in the treatment of liver metastasis with SRBT. BED is also an independent factor affecting OS.
Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Zhenfei Xiang,Jun Chen,Huanle Zhang,Li Shen,Qichun Wei

DOI: https://doi.org/10.1159/000371501

2015-01-01

Oncology Research and Treatment

Abstract:Background: The prognostic factors for patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy (WBRT)-based combined modality therapy were investigated. Materials and Methods: Out of 135 patients treated with WBRT, 47 (34.8%) received a radiation boost, 84 (62.2%) underwent systemic chemotherapy, and 39 (28.9%) were given epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Results: The mean survival time was 9.3 months, and the 1-year and 2-year survival rates were 46.3 and 16.1%, respectively. In univariate analysis, improved survival was associated with age < 60 years, no extracranial metastasis, Karnofsky performance score ≥ 70, ≥ 3 cycles of chemotherapy after diagnosis of brain metastases, combined treatment with EGFR-TKIs, and no metastases in the cerebellum. In multivariate analysis, the above prognostic factors maintained significance with the exception of age. In an additional analysis of the 58 patients with 1-3 brain metastases, combination of WBRT with radiation boost was associated with better survival. Conclusion: We confirm previously described prognostic factors. Moreover, we found the absence of cerebellar metastases to be an independent prognostic factor for favorable outcome.
Neutrophil-lymphocyte Ratio and Platelet-Lymphocyte Ratio Associations with Heart and Body Dose and Their Effects on Patient Outcomes in Locally Advanced Non-Small Cell Lung Cancer Treated with Definitive Radiotherapy.

Wu-Yan Xia,Xue-Ru Zhu,Wen Feng,Jun Liu,Jia-Ming Wang,Chang-Xing Lv,Qin Zhang,Wen Yu,Xu-Wei Cai,Xiao-Long Fu

DOI: https://doi.org/10.21037/tlcr-20-831

2020-01-01

Translational Lung Cancer Research

Abstract:Background: Inflammation plays a vital role in tumor growth and progression and can be affected by radiotherapy (RT) and chemotherapy. We sought to investigate the prognostic significance of neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), and their associations with dosimetric factors in locally advanced non-small cell lung cancer (LA-NSCLC). Methods: In this retrospective study, subjects consisted of 244 patients who had received definitive RT +/- chemotherapy for LA-NSCLC between 2012 and 2016. Absolute lymphocyte count (ALC), NLR and PLR recorded at pretreatment, during RT and post-RT were analyzed. Multivariable analysis (MVA) was performed to correlate clinical factors and inflammatory biomarkers with progression-free survival (PFS) and overall survival (OS) using a Cox regression model. Relationships between NLR or PLR with OS and PFS were evaluated with Kaplan-Meier analysis and compared with log-rank test results. Multiple stepwise linear regression was used to assess the associations between dosimetric factors and NLR or PLR. Results: The median PFS and OS for all patients were 8.6 and 15.8 months, respectively. On MVA for PFS and OS, higher 1-month post-RT start NLR [hazard ratio (HR) 1.049; 95% CI: 1.018-1.080; P=0.001] or higher 1-month post-RT start PLR (HR 1.001; 95% CI: 1.000-1.002; P<0.001) was associated with inferior PFS. Higher 1-month post-RT start NLR (HR 1.040; 95% CI: 1.013-1.069; P=0.004) or PLR (HR 1.001; 95% CI: 1.001-1.002; P< 0.001) was also an independent predictor of OS. ALCmin, baseline NLR and PLR were not associated with treatment outcomes. Multiple stepwise linear regression analysis confirmed that baseline NLR (P<0.001), heart V20 (P<0.001), heart V40 (P<0.001), and mean body dose (MBD) were significantly associated with 1-month post-RT start NLR. Also, baseline PLR (P<0.001) and MBD (P<0.001) were significantly associated with 1-month post-RT start PLR. Conclusions: Higher NLR and PLR during treatment were associated with worse patient outcomes, and heart dose or body dose was correlated with NLR or PLR in advanced NSCLC patients treated with definitive RT.
Consistency preserving in transaction processing on the Web

Kang-Woo Lee,Hyoung-Joo Kim

DOI: https://doi.org/10.1109/WISE.2000.882392

2000-06-19

Abstract:Electronic business processing has drastically grown since the advent of the World Wide Web. As transaction processing is at the heart of business processing, many companies have been interested in transaction processing on the Web. However, little attention has been paid to supporting consistent transaction processing on the Web, while most works have focused on performance enhancement, processing multiple HTTP requests in a single context, and scalability. This paper identifies three consistency problems in processing transactions on the Web and proposes solutions for each problem. These are based on cookie logging, Web page logging, and storing information for unilaterally aborted transactions. Some of the proposed ideas have been implemented in a Web transaction processing system, WebTP. We believe that they can be also applied to any other Web transaction processing system of similar architecture.
Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio predicts post-stereotactic radiosurgery survival of patients with brain metastases concurrently treated with immune checkpoint inhibitors

Shoji Yomo,Kyota Oda,Kazuhiro Oguchi

DOI: https://doi.org/10.3171/2024.5.JNS24259

2024-08-23

Abstract:Objective: Treatment with immune checkpoint inhibitors (ICIs) has shown clinical benefit for a wide range of cancer types. The neutrophil-to-lymphocyte ratio (NLR) reportedly correlates with survival time or progression-free survival in patients treated with ICIs. However, NLR has not yet been assessed in patients with brain metastases (BMs) receiving stereotactic radiosurgery (SRS) combined with concurrent ICIs. The authors investigated the predictive impact of NLR on the survival data of patients with BMs who received SRS with concurrent ICIs. Methods: The clinical records of patients who had undergone SRS with concurrent ICIs for BMs between January 2015 and August 2023 were retrospectively analyzed. NLR was calculated using the data obtained from the last examination prior to SRS. The optimal NLR cutoff value was identified by receiver operating characteristic (ROC) curve analysis for time-to-event data (overall survival [OS] ≤ 18 months). OS and intracranial disease progression-free survival (IC-PFS) rates were compared between the two NLR groups. Results: Of the 185 eligible patients included, 132 were male. The median (IQR) patient age was 69 (61-75) years. The primary cancers were lung, genitourinary, skin, breast, gastrointestinal, and others in 132, 23, 22, 2, 2, and 4 patients, respectively. The post-SRS median OS and IC-PFS times for the entire cohort were 18.4 (95% CI 14.0-23.1) months and 9.2 (95% CI 6.9-10.8) months, respectively. ROC curve analysis identified the optimal NLR cutoff value for 18-month OS to be 5.0 (area under the curve 0.64, Youden index 0.31). Kaplan-Meier analysis revealed that patients with high NLR (> 5) had a significantly shorter OS (median survival time 10.9 months for 48 patients vs 22.2 months for 137 patients, HR 2.0, 95% CI 1.3-3.0, p < 0.001). Similarly, a significant difference in median IC-PFS was noted: 4.8 months with high NLR versus 10.7 months with low NLR (HR 1.7, 95% CI 1.2-2.5, p = 0.003). Conclusions: The authors found elevated pre-SRS NLR (> 5) to be associated with shorter OS and IC-PFS after SRS with concurrent ICIs for BMs. NLR is a simple, cost-effective, and widely accessible biomarker, which can thus be used for managing patients with BMs receiving SRS concurrently with ICIs. Further investigation in other large datasets is, however, required to validate these findings.
Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients with Lung Oligometastases or Oligoprogression from Colorectal Cancer

Shuai Li,Dezuo Dong,Jianhao Geng,Xianggao Zhu,Chen Shi,Yangzi Zhang,Hongzhi Wang,Shun Zhou,Hao Wu,Yong Cai,Yongheng Li,Weihu Wang

DOI: https://doi.org/10.3389/fonc.2019.01080

IF: 4.7

2019-01-01

Frontiers in Oncology

Abstract:Purpose: To analyze the prognostic factors and optimal response interval for stereotactic body radiotherapy (SBRT) in patients with lung oligometastases (OM) or oligoprogression (OP) from colorectal cancer (CRC). Method: Patients with lung OM or OP from CRC treated by SBRT at our hospital were included in this retrospective review. The local control (LC), response to SBRT in different evaluation interval and regional metastases (RM) was analyzed. The risk factor for LC and RM was calculated using the Kaplan-Meier method and compared using the Log-rank test. Multivariate analysis with a Cox proportional hazards model was used to test independent significance. Results: A total of 53 patients with 105 lung metastases lesions treated from 2012 to 2018 were involved in this retrospective study. The median biologically effective dose (BED) for these patients was 100 Gy (range: 75-131.2 Gy). Complete response (CR) increased from 27 (25.7%) to 46 (43.8%) lesions at 1.8 and 5.3 months following SBRT, and at the last follow-up, 52 (49.5%) lesions achieved CR. The median follow-up duration for all patients was 14 months (range: 5-63 months), and 1-year LC was 90.4%. During the follow-up, 10 lesions suffered local relapse after SBRT (9 of them occurred within 8 months after SBRT). The univariate analysis shows BED ≥ 100 Gy (P = 0.003) and gross tumor volume (GTV) < 1.6 cm3 (P = 0.011) were better predictors for 1-year LC. The patients with lung oligoprogression had higher 1-year RM when compared with patients with lung oligometastases (hazard ratio 2.78; 95% confidence interval [CI] 1.04-7.48, P = 0.042). Until the last follow up, 4 (7.5%) patients suffered grade 2 radiation pneumonitis, and no grade 3-4 toxicity was observed. Conclusions: SBRT provides favorable LC in CRC patients with lung OM or OP, and the GTV and BED can affect the LC. Radiology examinations nearly 5-6 months following SBRT appear to represent the final local effect of SBRT, and the patients with oligoprogression has higher RM.
Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy

Xiaoming Yin,Haijun Chen,Yunchuan Sun,Li Xiao,Hongling Lu,Wei Guo,Hongjuan Yang,Jianxi Zhou,Kui Fan,Wei Liang

DOI: https://doi.org/10.1038/s41598-024-62662-3

IF: 4.6

2024-05-27

Scientific Reports

Abstract:In prior investigations, a correlation was established between patient outcomes in locally advanced non-small cell lung cancer (LA-NSCLC) following thoracic irradiation and parameters, such as pre/post-treatment neutrophil-to-lymphocyte ratio (NLR) and NLR change (ΔNLR). However, these parameters could potentially be influenced by radiation-related variables, such as gross tumor volume (GTV). The primary aim of this study was to elucidate the factors impacting post-treatment NLR and ΔNLR and to further assess their prognostic relevance. In this retrospective study, a cohort of 188 LA-NSCLC patients who underwent thoracic radiation between 2012 and 2017 was assessed. The calculation of pre/post-treatment NLR involved the use of absolute neutrophil and lymphocyte counts. ΔNLR was defined as the difference between post- and pre-treatment NLR values. To assess the relationships between various variables and overall survival (OS), local progression-free survival (LPFS), and distant metastasis-free survival (DMFS), the Kaplan–Meier technique and Cox proportional hazards regression were employed. Additionally, Spearman's rank correlation analysis was carried out to investigate correlations between the variables. The analysis revealed that both post-treatment NLR (r = 0.315, P < 0.001) and ΔNLR (r = 0.156, P = 0.032) were associated with GTV. However, OS, LPFS, and DMFS were not independently correlated with pre/post-treatment NLR. ΔNLR, on the other hand, exhibited independent associations with OS and DMFS (HR = 1.054, P = 0.020, and P = 0.046, respectively). Elevated ΔNLR values were linked to poorer OS ( P = 0.023) and DMFS ( P = 0.018) in the Kaplan–Meier analysis. Furthermore, when stratifying by GTV, a higher ΔNLR remained to be associated with worse OS and DMFS ( P = 0.047 and P = 0.035, respectively) in the GTV ≤ 67.41 cm 3 group, and in the GTV > 67.41 cm 3 group ( P = 0.028 and P = 0.042, respectively), highlighting ΔNLR as the sole independent predictive factor for survival and metastasis, irrespective of GTV.

multidisciplinary sciences
Analysis of Immunotherapy Combined with Radiotherapy in Patients with Brain Metastasis of Driver Gene-Negative Non-Small-Cell Lung Cancer

Shixiang Zhou,Hongmei Yin,Chaomang Zhu,Duojie Li,Xianming Li,Qun Zhcang

DOI: https://doi.org/10.1155/2022/1193075

2022-09-26

Abstract:Purpose. To observe the remission rate and side effects of immunotherapy combined with radiotherapy in patients with brain metastasis of driver gene-negative non-small-cell lung cancer (NSCLC). Methods. 152 patients with NSCLC brain metastasis admitted to our hospital from January 2019 to December 2021 were selected as the research objects. Patients were divided into a single group (85 cases) and a combined group (67 cases) according to treatment methods. The therapeutic effects and side effects of the single group and combined group were compared. In addition, the patients who received immunotherapy combined with radiotherapy were divided into three subgroups: A, B, and C, and the therapeutic effects and side effects of different radiotherapy modes were compared among group A [whole brain radiotherapy (WBRT)], group B (WBRT combined with local radiotherapy) and group C (local radiotherapy). Results. The objective response rate (ORR) and disease control rate (DCR) in the combined group were higher than those in the single group ( P < 0.05 ). The incidence of reactive capillary hyperplasia and immune-related pneumonia in the combined group were higher than that in the single group ( P < 0.05 ). There was no significant difference in the incidence of other side effects between the two groups ( P > 0.05 ). ORR and DCR in group B were higher than those in group A ( P < 0.05 ). There was no significant difference in the incidence of side effects among the three groups ( P > 0.05 ). Conclusion. Immunotherapy combined with radiotherapy is effective in patients with brain metastasis of driver gene-negative NSCLC, which can improve the disease control rate without increasing the side effects. In addition, WBRT combined with local push radiotherapy is effective and safe. Clinical Study Registration Number. The Clinical study registration number is K2019086.

integrative & complementary medicine
Immunoreactive gonadotropin-releasing hormone (GnRH) is detected only in the form of chicken GnRH-II within the brain of the green anole, Anolis carolinensis.

D. Lescheid,G. Rosen,A. Bridge,R. E. Jones,C. Warby,N. Sherwood

DOI: https://doi.org/10.1006/GCEN.1997.6970

IF: 3.255

1997-11-01

General and Comparative Endocrinology

Abstract:The presence of multiple forms of gonadotropin-releasing hormone (GnRH) within a single brain is common among vertebrate species. In previous studies of reptiles, two forms of GnRH were isolated from the brain of alligators and the primary structure was determined to be that of chicken (c)GnRH-I and cGnRH-II. GnRH has also been detected by indirect methods in other reptiles including turtles, lizards, and snakes. We used a combination of high-performance liquid chromatography (HPLC) and radioimmunoassay to determine the number and molecular form(s) of GnRH in the brain of a lizard, Anolis carolinensis, that was reported to lack GnRH cells in the forebrain. Immunoreactivity was detected in the same HPLC elution position in which synthetic cGnRH-II elutes, but not in any other position. Detection was based on five antisera that among them detect the 12 known forms of GnRH; these antisera include ones that are specific to cGnRH-I and cGnRH-II. We conclude that the lizard A. carolinensis contains cGnRH-II, but not cGnRH-I or another known form of GnRH. These data, coupled with our earlier immunocytochemical study, suggest that the lizard studied here lacks cGnRH-I, the form that is found in the terminal nerve, olfactory bulb, and forebrain in nonsquamate reptiles and in birds. Our hypothesis is that the presence of both cGnRH-I and cGnRH-II in the brain is ancestral in the reptilian lineage and retained in the orders that include turtles (Chelonia) or alligators (Crocodilia). However, the pattern in the order Squamata varies: in A. carolinensis, only cGnRH-II is present in the brain and cGnRH-I is absent, whereas in the snake Thamnophilis sirtalis, cGnRH-I is retained and cGnRH-II is absent in the brain, as recently reported. This raises the question of how reproduction is controlled in reptiles that lack one form of GnRH.
Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non‐small cell lung cancer undergoing stereotactic body radiotherapy

Fang Fang,Zhen Jia,Hongliang Xie,Yangsen Cao,Xiaofei Zhu,Xiao Yu Yang,Xueling Guo,Huojun Zhang

DOI: https://doi.org/10.1111/crj.13749

2024-05-01

The Clinical Respiratory Journal

Abstract:The relationship between blood inflammation biomarkers and survival in patients with locally advanced non‐small cell lung cancer undergoing stereotactic body radiotherapy (SBRT) remains unclear. This article presents that post‐SBRT biomarkers correlated with survival, and the decision tree model might play a role in future risk stratification to guide clinical practice. Background and Objective The neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) were significant and succinct indicators of systemic inflammation. We assessed the influence of stereotactic body radiotherapy (SBRT) on NLR and PLR in patients with locally advanced non‐small cell lung cancer (LA‐NSCLC). Methods We reviewed the medical data of patients with LA‐NSCLC who underwent SBRT between 1 January 2013 and 31 December 2018. NLR and PLR values recorded at pre‐ and post‐SBRT were examined. We assessed the correlation between pre/post‐SBRT NLR and PLR and survival outcomes. The decision tree evaluation was conducted using Chi‐square automatic detection. Results In total, 213 patients were included in the study with a median follow‐up duration of 40.00 (ranging from 5.28 to 100.70) months. Upon dichotomization by a median, we identified that post‐SBRT NLR > 5.5 and post‐SBRT PLR > 382.0 were negatively associated with shorter overall survival (OS). In the multivariate assessment, post‐SBRT PLR > 382.0 was the only factor. Based on post‐SBRT PLR, tumor locations, and tumor stage, we categorized patients into low, medium, or high‐risk groups. Conclusions Post‐SBRT PLR > 382.0 correlated with survival in patients undergoing SBRT. The decision tree model might play a role in future risk stratification to guide the clinical practice of individualized SBRT for LA‐NSCLC.

respiratory system
[Prognosis Analysis of Early-stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy]

Lu Yu,Junyi Li,Miaomiao Gao,Xiaofeng Wang,Hui Bai,Yong Guan,Zhiyong Yuan

DOI: https://doi.org/10.3779/j.issn.1009-3419.2023.102.13

2023-04-20

Abstract:Background: With the aging of the population and the increased importance of lung cancer screening, the number of early-stage lung cancer patients has been on the rise in recent years, which can be classified into operable early-stage lung cancer and inoperable early-stage lung cancer. The most common pathological type is non-small cell lung cancer (NSCLC). Stereotactic body radiation therapy (SBRT) is the optimal treatment for inoperable early-stage NSCLC. The aim of this study was to investigate the prognosis of early-stage NSCLC patients treated with SBRT and its influencing factors in order to reduce the side effects of radiotherapy and improve the survival and quality of life. Methods: Clinical data and follow-up outcomes of early-stage NSCLC patients treated with SBRT in our hospital from August 2010 to August 2020 were collected. Kaplan-Meier method was used to assess the prognosis, and the Cox proportional risk model was used for multivariate prognostic analysis. Results: A total of 165 patients were included with a median follow-up time of 43.2 (range: 4.8-132.1) mon. The local control (LC) rates at 1-yr, 2-yr and 5-yr were 98.1%, 94.8% and 86.5% respectively. Karnofsky performance status (KPS) score greater than 80 was an independent prognostic factor for LC (P=0.02). The overall survival (OS) rates at 1-yr, 2-yr and 5-yr were 97.6%, 93.0% and 68.9% respectively. A biological equivalent dose when α/β=10 (BED10) greater than 132 Gy was an independent prognostic factor for OS (P=0.04). Progression-free survival (PFS) rates at 1-yr, 2-yr and 5-yr were 93.3%, 79.5% and 55.3% respectively. The distance metastasis free survival (DMFS) rates at 1-yr, 2-yr and 5-yr were 94.5%, 83.2% and 58.4% respectively. BED10 greater than 150 Gy was an independent prognostic factor for DMFS (P=0.02). The regional control (RC) rates at 1-yr, 2-yr and 5-yr were 98.8%, 95.4% and 87.9% respectively. Conclusions: SBRT is effective in treating early-stage NSCLC. KPS greater than 80 is an independent prognostic factor for LC; BED10 greater than 132 Gy is an independent prognostic factor for OS; BED10 greater than 150 Gy is an independent prognostic factor for DMFS.
Pretreatment Neutrophil to Lymphocyte Ratio is Associated with Response to Therapy and Prognosis of Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy

Yanwen Yao,Dongmei Yuan,Hongbing Liu,Xiaoling Gu,Yong Song

DOI: https://doi.org/10.1007/s00262-012-1347-9

IF: 6.63

2012-01-01

Cancer Immunology Immunotherapy

Abstract:BACKGROUND:Neutrophil to lymphocyte ratio (NLR) has been shown to be a prognosis indicator in different types of cancer. We aimed to investigate the association between NLR and therapy response, progression free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy.METHODS:Patients who were hospitalized between January 2007 and December 2010 were enrolled and eliminated according to the inclusion and exclusion criteria. The NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count. Logistic regression analysis was applied for response rate and Cox regression analysis was adopted for PFS and OS. A P value of ≤0.05 was considered to be statistically significant.RESULTS:A total of 182 patients were enrolled in the current study. The median PFS was 164.5 days and median OS was 439.5 days. The statistical analysis data indicated that low pretreatment NLR (≤ 2.63) (OR = 2.043, P = 0.043), decreased posttreatment NLR (OR = 2.368, P = 0.013), well and moderate differentiation (OR = 2.773, P = 0.021) and normal CEA level (≤ 9.6 ng/ml) (OR = 2.090, P = 0.046) were associated with response to first-line platinum-based chemotherapy. A high pretreatment NLR (HR = 1.807, P = 0.018 for PFS, HR = 1.761, P = 0.020 for OS) and distant metastasis (HR = 2.118, P = 0.008 for PFS, HR = 2.753, P = 0.000 for OS) were independent prognostic factors for PFS and OS.CONCLUSION:Elevated pretreatment NLR might be a potential biomarker of worse response to first-line platinum-based chemotherapy and shorter PFS and OS for advanced NSCLC patients. To confirm these findings, larger, prospective and randomized studies are needed.
[Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].

X Dong,Z M Zhou,N Bi,J B Wang,J T Ran,Z G Hui,J Liang,Q F Feng,D F Chen,Z F Xiao,J M Lyu,X Z Wang,X Wang,T Zhang,L Deng,W Q Wang,L H Wang

DOI: https://doi.org/10.3760/cma.j.issn.0253-3766.2018.06.009

2018-01-01

Abstract: The aim of this retrospective study was to evaluate the prognostic significance of pretreatment Neutrophil-to-Lymphocyte Ratio(NLR) in locally advanced non-small cell lung cancer(NSCLC) patients treated with thoracic radiotherapy. We retrospectively analyze 420 patients who received thoracic radiotherapy alone, sequential chemoraiotherapy or concurrent chemoradiotherapy for locally advanced stage NSCLC from January 2007 to December 2010 of our hospital. The patients were divided into two groups (high NLR group and low NLR group) with appropriate cutoff point using the receiver operating characteristic (ROC) curve method. The survival curve was established by Kaplan-Meier method. The Log-rank test was used to compare the survival of the two NLR groups and the multivariate analysis was carried out by Cox regression model. Among the 420 patients, 99 received radiotherapy alone, 139 received sequential chemoradiotherapy and 182 received concurrent chemoradiotherapy. 345 patients died and 75 were still alive. The median follow-up time was 5.2 years and the median overall survival was 22 months. The cut-off value of pretreatment NLR was 2.1. The 5-year PFS and OS rates in high NLR group and low NLR group were 10.6% vs 15.7% (=0.033) and 15.5% vs 22.7% (=0.012). Multivariate analysis confirmed that pretreatment NLR (hazard ratio 1.06, =0.041) was independent prognostic factor of OS. Our study revealed that the pretreatment NLR is the independent prognostic factor of OS in patients with locally advanced stage NSCLC treated with thoracic radiotherapy. However, NLR is still greatly influenced by patient's condition and treatment which needs further research.
Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy

Xiao-mei Zhao,Bao-ying Yuan,Zhuang Yuan,Yong Hu,Yixing Chen,Li Zhang,Gen-wen Chen,Z. Zeng

DOI: https://doi.org/10.2147/CMAR.S231901

2019-12-31

Cancer Management and Research

Abstract:Purpose The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are inflammatory indexes that may reflect immune response to tumors and prognosis. We investigated the prognostic values of pre-treatment and post-treatment NLR and PLR and changes in those ratios in patients with small hepatocellular carcinoma (sHCC) treated with stereotactic body radiation therapy (SBRT). Patients and methods Sixty patients who received SBRT were retrospectively reviewed. NLR and PLR were calculated by division of neutrophil and platelet counts, respectively, by lymphocyte counts. Independent factors for progression-free survival (PFS) and overall survival (OS) were determined by the Kaplan–Meier method, log-rank test, and Cox multivariate regression. Hazard ratios (HRs) and 95% confidence intervals (CIs) were also calculated. Results The median follow-up was 36.9 (range: 4.1–73.5) months. Median PFS was 21.4 (range: 1.8–66.9) months. The 1-year and 2-year PFS rates were 76.7% and 55.0%, respectively. The 1-year and 2-year OS rates were 95.0% and 78.3%, respectively. In multivariate analysis, post-treatment PLR ≥263.0 indicated both poor PFS (HR: 3.70; 95% CI: 1.07–12.76, p=0.038) and OS (HR: 3.23; 95% CI: 1.01–9.11, p=0.043) for sHCC patients treated with SBRT. In addition, the presence of hepatitis infection and a low level of red blood cell count were also proved to be significantly associated with patients’ poor prognosis (p<0.05 for each). Post-treatment increase in NLR ≥2.7-fold was shown to be a negative independent predictor of inferior OS (HR: 3.43; 95% CI: 1.14–10.38, p=0.029). Conclusion High post-treatment PLR and change in NLR ≥2.7-fold were associated with poor prognosis in patients treated with SBRT and might be considered as reliable and independent prognostic biomarkers for patients with sHCC.

Medicine
Radiation-Induced Lymphopenia and Its Impact on Survival in Patients with Brain Metastasis

Naoko Ishida,Yukinori Matsuo,Junki Fukuda,Aritoshi Ri,Saori Tatsuno,Takuya Uehara,Masahiro Inada,Tomohiro Matsuura,Hiroshi Doi,Kiyoshi Nakamatsu,Makoto Hosono

DOI: https://doi.org/10.3390/curroncol31080340

2024-08-09

Abstract:Background: Differences in radiation-induced lymphopenia and prognosis between methods of radiotherapy (RT) for brain metastases remain unclear. Methods: In this retrospective analysis of patients who underwent whole-brain radiotherapy (WBRT) or stereotactic radiosurgery/radiotherapy (SRS/SRT) for brain metastases, baseline total lymphocyte count (TLC) data were obtained within 2 weeks before RT initiation. Follow-up TLC data were evaluated at 0-2, 2-4, and 4-8 weeks after RT completion. Persistent lymphopenia was defined as <800/μL at any time point. Results: Overall, 138 RT courses in 128 patients were eligible (94 WBRT; 44 SRS/SRT). In the WBRT courses, the median baseline TLC was 1325/μL (IQR: 923-1799). Follow-up TLC decreased significantly to 946/μL (626-1316), 992/μL (675-1291), and 1075/μL (762-1435) (p < 0.001). SRS/SRT courses showed no significant TLC decrease. Multivariate analysis revealed female sex, prior RT, baseline TLC < 800/μL, and WBRT use were significantly associated with persistent lymphopenia. In the WBRT group, overall survival was significantly different between those with and without persistent lymphopenia (median, 2.6 and 6.1 months; p < 0.001). However, there was no significant difference in survival in the SRS/SRT group (p = 0.60). Conclusion: This study suggests SRS/SRT might be preferable for lymphocyte preservation in brain metastasis patients.
Relationship Between Neutrophil-To-Lymphocyte Ratio and Brain Metastasis in Non-Small Cell Lung Cancer Patients

Chunxiao Hu,Jing Wu,Yafeng Liu,Jiawei Zhou,Wenyang Wang,Xueqin Wang,Jianqiang Guo,Qingsen Wang,Xin Zhang,Danting Li,Jun Xie,Xuansheng Ding,Yingru Xing,Dong Hu

DOI: https://doi.org/10.1177/10732748221076805

Cancer Control

Abstract:Objective: To investigate the relationship between the neutrophil-to-lymphocyte ratio (NLR) of patients with non-small cell lung cancer (NSCLC) and their risk of developing brain metastases after adjusting for confounding factors. Methods: A retrospective observational study of the general data of patients with NSCLC diagnosed from January 2016 to December 2020. Multivariate logistic regression was used to calculate the dominance ratio (OR) with 95% confidence interval (CI) for NLR and NSCLC brain metastases with subgroup analysis. Generalized summation models and smoothed curve fitting were used to identify whether there was a nonlinear relationship between them. Results: In all 3 models, NLR levels were positively correlated with NSCLC brain metastasis (model 1: OR: 1.12, 95% CI: 1.01-1.23, P = .025; model 2: OR: 1.16, 95% CI: 1.04-1.29, P = .007; model 3: OR: 1.20, 95% CI: 1.05-1.37, P = .006). Stratified analysis showed that this positive correlation was present in patients with adenocarcinoma (LUAD) and female patients (LUAD: OR: 1.30, 95% CI: 1.10-1.54, P = .002; female: OR: 1.52, 95% CI: 1.05-2.20, P = .026), while there was no significant correlation in patients with squamous carcinoma (LUSC) and male patients (LUSC: OR:0.76,95% CI:0.38- 1.53, P = .443; male: OR:1.13, 95% CI:0.95-1.33, P = .159). Conclusion: This study showed that elevated levels of NLR were independently associated with an increased risk of developing brain metastases in patients with NSCLC, and that this correlation varied by TYPE and SEX, with a significant correlation in female patients and patients with LUAD.
The Incidence and Prognosis of Brain Metastasis after Radical Chemoradiotherapy in Non-Small Cell Lung Cancer

Zhu Hong,Xu Yin,Fan Xingwen,Wang Hongbing,Yang Yanqin,Li Yunhai,Wu Kailiang

DOI: https://doi.org/10.3760/cma.j.issn.2096-5400.2019.02.007

2019-01-01

Abstract:Objective The prognosis of lung cancer brain metastasis is affected by many factors.This study was to analyze the incidence of brain metastasis (BM) in patients with stage Ⅱ-Ⅲ non-small cell lung cancer (NSCLC),undergoing radical chemoradiotherapy,and to study the factors affecting prognosis of survival.The values of DS-GPA and Lung-mol GPA,two prognostic index models,were compared in prognosis of patients with specific BM types.Methods A total of 98 patients with stage Ⅱ-Ⅲ NSCLC who underwent radical ehemoradiotherapy were enrolled into the database of the Cancer Hospital of Fudan University,from January 2005 to December 2014.A total of 98 patients with brain metastases after treatment were screened and collected.Univariate and multivariate analyses were performed on factors that may affect their survival prognosis.The survival rate was compared using the Log-rank test.The abilities of the two prognostic index models to predict survival were compared by ROC's area under the curve (AUC).Results The incidence of brain metastases in patients with stage Ⅱ-Ⅲ primary NSCLC after radical chemoradiotherapy was 12.6％.Univariate analysis showed that gender,brain metastasis KPS score,pathological type,initial clinical stage,gene status,TKI treatments,brain radiotherapy had an effect on patients' survival (P＜ 0.05);multivariate analysis showed that gene status,brain metastasis KPS score and TKI treatments were closely related to survival (P＜0.05).The AUC of the DS-GPA model predicted survival was 0.588,and the AUC of the Lung-mol GPA model was 0.608.Conclusions The gene status,TKI treatment,and KPS scores of BM patients are related to survival in this study.The two prognostic index models of DS-GPA and Lung-mol GPA have limited application value for prognosis evaluation of these patients.New prediction models need to be further validated and explored in large sample populations.
Radiotherapy in Different Doses for Non-Small Cell Lung Cancer Patients with Brain Metastasis-Phase Ⅰ-Ⅱ Study

杨焕军,张福林,蒋国梁,付小龙,钱浩,王丽娟

DOI: https://doi.org/10.3760/j.issn:1004-4221.2003.04.003

2003-01-01

Abstract:Objective To observe the tolerance , effectiveness and prognostic factors of three different doses for non-small cell lung cancer (NSCLC) patients with brain metastasis. Methods Seventy-five NSCLC patients with known brain metastasis were irradiated in the following protocols. Group A whole brain irradiation to 30 ?Gy/10 fractions over 2 weeks then boosted to 45?Gy/15 fractions over 3 weeks for patients with only one lesion in the brain without any extracranial involvement(14 cases).Group B whole irradiation to 39?Gy/13 fractions over 2.5 weeks for patients with more than one lesion in the brain also without any extracranial involvement (29 cases). Group C whole irradiation to 30 ?Gy/10 fractions over 2 weeks for patients with both extracranial and brain lesions(32 cases). Results The incidence of symptom relief (pain,nausea and vomiting) was 100% in all groups.The incidences of neurological sign relief in groups A、B、C were 100%(7/7),86%(12/14),93%(14/15). The overall median local control duration was 7.6 months (0.8-52.7 months) . The overall 1-and 2-year local control rates were 46% and 23%.The 1-and 2-year local control rates of groups A, B,C were 55% and 38%, 52% and 26%, 33% and 10%,respectively. The overall median survival was 9.6 months (0.8-52.8 months). The overall 1-and 2-year survival rates were 49% and 26%.The 1-and 2-year survival rates of groups A, B,C were 53% and 49%,50% and 23%,45% and 9%,respectively. Side effects: None of these patients showed serious acute side effects except one in group A who developed gastrointestinal bleeding and one in group C who had epileptic seizures during the second session of irradiation. Late effects:Two patients in group B showed impairment in thought coherence and behavior though without any tumor in the brain after 23,17 months of irradiation. The results of Cox regression in local control suggested that higher dose may give better local control duration (P=0.003). And another result of Cox regression in the overall survival showed that KPS and local control of brain tumor might influence the overall survival duration(P=0 .0 5 1,0 .056) .Conclusions This protocol gives satisfactory local control and local control duration without necessitating over-treatment in some patients.It warrants further study .
[Methods, developments and applications of circular dichroism and simultaneous dual CD/UV spectroscopy in analytical chemistry].

P. Horváth

2001-08-01

Acta Pharmaceutica Hungarica

Abstract:Circular dichroism (CD) is one of the few sensitive indicators of molecular configuration. CD spectroscopy has therefore long been used for structure elucidation. Recent trends show, however, an enormous progress of CD spectroscopy in analytical chemistry, either as an independent method, or as a detector in hyphenated separation techniques. Its uses became especially widespread in pharmaceutical analyses, since enantiomeric purity is a crucial criterion of drug quality. Objectives of the present Ph.D. work included fundamental research in CD and related methodologies, but also, its applications in pharmaceutical analysis. A technical prerequisite of our research work was the instrumental hyphenation of separation and chiroptical detection techniques, which has been achieved by the combination of high performance liquid chromatographic and circular dichroism spectroscopic devices. Our home-built apparatus was the first HPLC-CD instrument in Hungary. Its uses allowed the elaboration of a new method for the determination of peak homogeneity, which applies simultaneous, dual CD/UV detection, and a subsequent ratio-formation. An improved version of this method resulted in the deconvolution of overlapping chromatographic peaks. Another type of peak homogeneity control method was elaborated by rapid, on-line recording of CD spectra in the progress of elution, in order to analyse apparently homogeneous peaks. Circular dichroism has also been applied to quantitate enantiomeric purity in composite samples without any separation of the analytes, and also, to determine equilibrium constants of protonating chiral compounds.
Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation

Zhe Ji,Nan Bi,Jingbo Wang,Zhouguang Hui,Zefen Xiao,Qinfu Feng,Zongmei Zhou,Dongfu Chen,Jima Lv,Jun Liang,Chengcheng Fan,Lipin Liu,Luhua Wang

DOI: https://doi.org/10.1016/j.ijrobp.2014.02.025

2014-06-01

Abstract:Purpose: We intended to identify risk factors that affect brain metastases (BM) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving definitive radiation therapy, which may guide the choice of selective prevention strategies. Methods and materials: The characteristics of 346 patients with stage III NSCLC treated with thoracic radiation therapy from January 2008 to December 2010 in our institution were retrospectively reviewed. BM rates were analyzed by the Kaplan-Meier method. Multivariate Cox regression analysis was performed to determine independent risk factors for BM. Results: The median follow-up time was 48.3 months in surviving patients. A total of 74 patients (21.4%) experienced BM at the time of analysis, and for 40 (11.7%) of them, the brain was the first site of failure. The 1-year and 3-year brain metastasis rates were 15% and 28.1%, respectively. In univariate analysis, female sex, age ≤60 years, non-squamous cell carcinoma, T3-4, N3, >3 areas of lymph node metastasis, high lactate dehydrogenase and serum levels of tumor markers (CEA, NSE, CA125) before treatment were significantly associated with BM (P<.05). In multivariate analysis, age ≤60 years (P=.004, hazard ratio [HR] = 0.491), non-squamous cell carcinoma (P=.000, HR=3.726), NSE >18 ng/mL (P=.008, HR=1.968) and CA125 ≥ 35 U/mL (P=.002, HR=2.129) were independent risk factors for BM. For patients with 0, 1, 2, and 3 to 4 risk factors, the 3-year BM rates were 7.3%, 18.9%, 35.8%, and 70.3%, respectively (P<.001). Conclusions: Age ≤60 years, non-squamous cell carcinoma, serum NSE >18 ng/mL, and CA125 ≥ 35 U/mL were independent risk factors for brain metastasis. The possibilities of selectively using prophylactic cranial irradiation in higher-risk patients with LA-NSCLC should be further explored in the future.

[Comparison of intracellular actin of thymosin alpha-1 and thymic serum factor].

Neutrophil-lymphocyte Ratio As a Prognostic Factor for Stereotactic Body Radiotherapy Treatment of Metastatic Liver Tumors.

Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Neutrophil-lymphocyte Ratio and Platelet-Lymphocyte Ratio Associations with Heart and Body Dose and Their Effects on Patient Outcomes in Locally Advanced Non-Small Cell Lung Cancer Treated with Definitive Radiotherapy.

Consistency preserving in transaction processing on the Web

Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio predicts post-stereotactic radiosurgery survival of patients with brain metastases concurrently treated with immune checkpoint inhibitors

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients with Lung Oligometastases or Oligoprogression from Colorectal Cancer

Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy

Analysis of Immunotherapy Combined with Radiotherapy in Patients with Brain Metastasis of Driver Gene-Negative Non-Small-Cell Lung Cancer

Immunoreactive gonadotropin-releasing hormone (GnRH) is detected only in the form of chicken GnRH-II within the brain of the green anole, Anolis carolinensis.

Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non‐small cell lung cancer undergoing stereotactic body radiotherapy

[Prognosis Analysis of Early-stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy]

Pretreatment Neutrophil to Lymphocyte Ratio is Associated with Response to Therapy and Prognosis of Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy

[Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].

Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy

Radiation-Induced Lymphopenia and Its Impact on Survival in Patients with Brain Metastasis

Relationship Between Neutrophil-To-Lymphocyte Ratio and Brain Metastasis in Non-Small Cell Lung Cancer Patients

The Incidence and Prognosis of Brain Metastasis after Radical Chemoradiotherapy in Non-Small Cell Lung Cancer

Radiotherapy in Different Doses for Non-Small Cell Lung Cancer Patients with Brain Metastasis-Phase Ⅰ-Ⅱ Study

[Methods, developments and applications of circular dichroism and simultaneous dual CD/UV spectroscopy in analytical chemistry].

Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation